ZA200207235B - Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals. - Google Patents
Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals. Download PDFInfo
- Publication number
- ZA200207235B ZA200207235B ZA200207235A ZA200207235A ZA200207235B ZA 200207235 B ZA200207235 B ZA 200207235B ZA 200207235 A ZA200207235 A ZA 200207235A ZA 200207235 A ZA200207235 A ZA 200207235A ZA 200207235 B ZA200207235 B ZA 200207235B
- Authority
- ZA
- South Africa
- Prior art keywords
- carnitine
- vitamin
- fat soluble
- substance
- composition
- Prior art date
Links
- 229940088594 vitamin Drugs 0.000 title claims description 101
- 229930003231 vitamin Natural products 0.000 title claims description 101
- 235000013343 vitamin Nutrition 0.000 title claims description 101
- 239000011782 vitamin Substances 0.000 title claims description 101
- 238000000034 method Methods 0.000 title claims description 80
- 241001465754 Metazoa Species 0.000 title claims description 57
- 230000031891 intestinal absorption Effects 0.000 title claims description 19
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 108
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 91
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 42
- 239000000126 substance Substances 0.000 claims description 40
- 235000005911 diet Nutrition 0.000 claims description 36
- 235000019165 vitamin E Nutrition 0.000 claims description 33
- 239000011709 vitamin E Substances 0.000 claims description 33
- 229930003427 Vitamin E Natural products 0.000 claims description 30
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 30
- 229940046009 vitamin E Drugs 0.000 claims description 30
- 230000037213 diet Effects 0.000 claims description 29
- 238000010521 absorption reaction Methods 0.000 claims description 27
- 229960004203 carnitine Drugs 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 210000004185 liver Anatomy 0.000 claims description 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
- 230000010234 biliary secretion Effects 0.000 claims description 12
- 208000002780 macular degeneration Diseases 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 11
- 235000019155 vitamin A Nutrition 0.000 claims description 11
- 239000011719 vitamin A Substances 0.000 claims description 11
- 208000029078 coronary artery disease Diseases 0.000 claims description 10
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 229940011871 estrogen Drugs 0.000 claims description 8
- 239000000262 estrogen Substances 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- 241000282326 Felis catus Species 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 208000019622 heart disease Diseases 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 208000014001 urinary system disease Diseases 0.000 claims description 5
- RZALONVQKUWRRY-XOJLQXRJSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-XOJLQXRJSA-N 0.000 claims description 4
- VIOYPGDQEDDCJB-UUCJDPIKSA-H trimagnesium;2-hydroxypropane-1,2,3-tricarboxylate;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound [Mg+2].[Mg+2].[Mg+2].C[N+](C)(C)C[C@H](O)CC([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VIOYPGDQEDDCJB-UUCJDPIKSA-H 0.000 claims description 4
- AYAHVULUMILDAD-FYZOBXCZSA-N hexanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)CCCCC(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O AYAHVULUMILDAD-FYZOBXCZSA-N 0.000 claims description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 37
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000002485 urinary effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 32
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 24
- 210000002751 lymph Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000000378 dietary effect Effects 0.000 description 7
- -1 phospholipid fatty acid Chemical class 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 6
- 229960003132 halothane Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000001926 lymphatic effect Effects 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 210000000941 bile Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000011732 tocopherol Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 229940117972 triolein Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 210000001953 common bile duct Anatomy 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 210000002599 gastric fundus Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920000260 silastic Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- WIHBNMPFWRHGDF-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[2-[[2-[[6-amino-2-[[4-amino-2-[[2-[(2-aminoacetyl)amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]propanoylamino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4 Chemical compound CSCCC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(C(C)CC)NC(=O)C(C(C)CC)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)CN WIHBNMPFWRHGDF-UHFFFAOYSA-N 0.000 description 1
- STRVVRPNBAHXRJ-UHFFFAOYSA-N 2-hydroxynon-2-enal Chemical compound CCCCCCC=C(O)C=O STRVVRPNBAHXRJ-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001071861 Lethrinus genivittatus Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
¥ ~
METHOD FOR INCREASING INTESTINAL ABSORPTION
OF FAT SOLUBLE VITAMINS IN POST-MENOPAUSAL WOMEN 0 AND LOWER ANIMALS
This invention relates to a method for increasing the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and/or liver concentration of a fat soluble vitamin in a post-menopausal woman or a lower animal by orally administering L- carnitine and a fat soluble vitamin. }
L-carnitine plays a crucial role in the energy supply of tissues by modulating the entry of long-chain fatty acids into the mitochondrial matrix: and their subsequent oxidation. Consistent with such a metabolic role, L-camitine has been shown to be effective in lowering the serum levels of cholesterol, triglyceride, and free fatty acids, while increasing high density lipoprotein (HDL) cholesterol which is antiatherogenic. See Pola, P. et al, ’ “Carnitine in the theraphy of dyslipemic patients", Curr Ther Res 27:208-16 (1980); Lacour,
B. et al., "Carnitine improves lipid abnormalies in haemodialysis patients”, Lancer 12:763-4 (1980); Avogaro, P., "Acute effect of L-carnitine on FFA and beta-hydroxy-butyrate in man",
Pharmacol Res Commun 13:433-50 (1981); and Vacha, G.M. ez al. "Favourable effects of L- carnitine treatment on hypertriglyceridemia in hemodialysis patients: Decisive role of low levels of high density lipoprotein cholesterol", Am J Clin Nutr 38:532-40 (1983). Existing
¥ « - evidence indicates that L-carnitine and its esters enhance the stability and integrity of : ervthrocyte membranes by participating in the reacylation (repair) of membrane phospholipids subjected to oxidative damage. See Arduini, A. et al., "Effect of propionyl-L-camnitine ‘ treatment on membrane phospholipid fatty acid tumover in diabetic rat erythrocytes”, Mol 5 Cell Biochem 152:31-7 (1995); Arduini, A. et al., "Carnitine palmitoyltransferase and acyl-
CoA binding protein: two more players in the membrane phospholipid fatty acid turnover of human red cells?", Biochem J 325:811-4 (1997); and Arduini, A. et al., "Addition of L- carnitine to additive solution-suspended red cells stored at 4 °C reduces in vitro hemolysis and improves in vivo viability", Trandfusion 37:166-74 (1997). It is of interest to note that such an action of L-carnitine and its esters is shown in the erythrocyte devoid of mitochondria. L- carnitine supplementation to old rats has been shown to reverse the age-related decline in mitochondrial function, which may be linked to the membrane-stabilizing effect of L- carnitine. See Hagen, T.M. et al, "Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity", Proc Natl Acad Sci USA 95:9562-6 (1998).
This finding is of particular significance in that oxidative damage to mitochondrial DNA increases markedly with age, leading to impaired cellular metabolism and function. See
Hagen, T.M. et al., "Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase", Proc Natl Acad Sci USA 94:3064-9 (1997).
Postmenopausal women make up over 15% of the total population in industrialized countries. By 2030, the proportion of postmenopausal women is predicted to increase to 23% of the total population. See Hill, K., "The demography of menopause”,
Maturitas 23:113-127 (1996). In addition, numerous epidemiological studies have shown that depletion of estrogen at the menopause influences cause-specific morbidity and mortality in later life. From the nutritional standpoint, the menopause is the time when the body’s ability to absorb, assimilate, and metabolize nutrients begins to deteriorate. Consequently, the body status of nutrients is compromised at and after menopause, with the manifestations of specific nutrient deficiency symptoms with time.
It is well documented that postmenopausal women are substantially more ) susceptible to coronary heart disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer’s disease. See Hill, K., "The demography of menopause", Maturitas 23:113- 127 (1996). Although this is partly associated with the process of aging and deterioration of bodily functions and the immune systems, epidemiological evidence suggests that a significant association exists between the risks (or incidence) of certain chronic diseases and the inadequacies or deficiencies of specific nutrients in postmenopausal women. Current v « 3 - evidence strongly suggests that the compromised body status of lipid-soluble vitamins, such . as vitamins A, D, and E, is a key factor influencing or contributing to the onset or development of the diseases. For example, the risk of coronary heart disease rises . dramatically in postmenopausal and ovariectomized women, compared with women in their
S child-bearing years. Supplemental vitamin E has been shown to reduce significantly the risk of coronary heart disease by retarding the oxidation of serum lipoproteins and inhibiting the proliferation of vascular smooth muscle cells. See Chan, A.C., "Vitamin E and atherosclerosis”, J Nutr 128:1593-6 (1998); Motoyama, T. et al., "Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spasmic angina", J Am Coll Cardiol 32:1672-9 (1998); and Meydani, M. et al., "The effect of long-term dietary supplementation with antioxidants", Ann NY Acad Sci 854:352-60 (1998). Also, it is well established that vitamin D deficiency is prevalent in postmenopausal women with increased risk for bone loss and osteoporosis. See WHO Scientific Group, "Research on the menopause in the 1990s", WHO Technical Report, Series 866, 1996, WHO,
Geneva, Switzerland. Also, studies have shown that the incidence of age-related macular degeneration in postmenopausal women is inversely correlated with intakes of provitamin A (carotenoids) and vitamin E. See Seddon, J.M. ef al., "Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye disease case-control study group*,
JAMA 272:1413-20 (1994); West, S. et al., "Are antioxidants or supplements protective for age-related macular degeneration?", Arch Opthalmol 112:222-7(1994); Vander Hagen, A M.,, et al., "Free radicals and antioxidant supplementation: a review of their roles in age-related macular degeneration", J Am Optom Assoc 64:871-8 (1993); and Golberg, J. et al., "Factors associated with age-related macular degeneration. An analysis of data from first National
Health and Nutrition Examination Survey", AmJ Epidemiol 128:700-10 (1988). Furthermore, recent evidence suggests that oxidative stress may play an important role in the pathogenesis of Alzheimer’s disease and that supplemental vitamin E may lower the risk of the disease.
See Sinclair, A.J. et al., "Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia", Int J Geriatr Psychiatry 13:840-5 (1998); Morris, M.C., ef ! : al., "Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease",
Alzheimer Dis Assoc Disord 12:121-6 (1998); Subramaniam, R. ef al., "The free radical ) antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer’s disease", Neurochem Res 23:1403-10 (1998).
.
It has also been shown that cancer accounts for 47% of disease-related deaths . in dogs followed by heart diseases (12%) and kidney diseases (7%). In cats, top ranking diseases include cancer (32%), kidney/urinary diseases (23%), and heart diseases (9%). See
Morris Animal Foundation Animal Health Survey 1997. It is thought that these diseases in animals are associated with inadequate levels of certain vitamins, especially antioxidant vitamins like vitamin E and vitamin C, as well as vitamin A.
Therefore, there is a need for improving the nutritional status of the fat-soluble vitamins in postmenopausal women, particularly, considering the decreased efficiency of nutrient absorption and deterioration of the intestinal absorptive function with aging in general. There is also a need for improving the nutritional status of the fat-soluble vitamins in lower animals, particularly, considering deterioration of the intestinal absorptive function with aging in general.
Applicants have discovered that L-carnitine increases the intestinal (lymphatic) absorption of fat soluble vitamins, such as vitamins A, D, and E, in post-menopausal women.
As a result, L-carnitine enhances the antioxidant defense mechanism and lowers the risk of certain degenerative diseases, such as coronary heart disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer's, in post-menopausal women.
The present invention provides a method for increasing the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and/or liver concentration of a fat soluble vitamin in a post-menopausal woman. The method comprises orally administering to a post-menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine.
The invention also provides a method of reducing the risk of or preventing one or more diseases in a post-menopausal woman selected from coronary heart disease, age- related macular degeneration, osteoporosis, cancer, and Alzheimer's. The method comprises orally administering to a post-menopausal woman in need thereof, a fat soluble vitamin and ' a fat soluble vitamin absorption increasing effective amount of L-carnitine.
The invention provides a method for increasing the intestinal absorption of a fat soluble vitamin in an animal. The method comprises orally administering to the animal in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine.
v - - or The invention also provides a method of reducing the risk of or preventing nue . or more diseases in an animal selected from heart diseases, including coronary heart disease; kidney diseases; urinary diseases; and cancer. The method comprises orally administering to . an animal in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption 5 increasing effective amount of L-carnitine.
Figure 1 is an illustration of biliary secretion of a-tocopherol (aTP) at hourly intervals for 8 hours. The control group is represented as -CN (i.e. without carnitine). The carnitine containing group is represented as +CN. All values are expressed as mean + standard deviation (SD). 5 rats were tested per time point (i.e. n=5). .
Figure 2 is an illustration of cumulative biliary secretion of a-tocopherol (a TP) at hourly intervals for 8 hours. The control group is represented as -CN (i.e. without carnitine). The carnitine containing group is presented as +CN. All values are expressed as mean SD. § rats were tested per time point (i.e. n= 15). Asterisks (*) denote significant differences at p < 0.05.
Figure 3 is an illustration of lymphatic absorption of a-tocopherol (oTP) at hourly intervals for 8 hours. The control group is represented as SN. The carnitine containing group is represented as CK. All values are expressed as mean = SD. 5 rats were tested per time point (i.e. n = 5). Asterisks (*) denote significant differences at p < 0.05.
Figure 4 is an illustration of cumulative lymphatic absorption of a-tocopherol (oTP) at hourly intervals for 8 hours. The control group is represented as SN. The carnitine containing group is CK. All values are expressed as mean + SD. 5 rats were tested per time point (i.e. n = 5). Asterisks (*) denote significant differences at p < 0.05. :
The present invention provides a method for increasing the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and liver concentration ) of a fat soluble vitamin in a post-menopausal woman. The method comprises orally administering to a post-menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine.
In like matter, the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and liver concentration of a fat soluble vitamin can be increased in a lower animal, such as a cat or dog, by orally administering to a lower animal in need thereof, a fat v soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L- . carnitine.
Suitable L-carnitines include, but are not limited to, L-carnitine; acyl-L-
N carnitines, such as acetyl L-carnitine, propionyl-L-carnitine, butanyl-L-carnitine, valeryl L- carnitine, and isovaleryl L-carnitine; pharmaceutically acceptable salts thereof; and any combination of any of the foregoing. Suitable pharmaceutically acceptable salts of L-carnitine include, but are not limited to, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bromide, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, chloride, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glucose phosphate, glycerophosphate, hemisulfate, heptanoate, hexanoate, iodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, methane sulphonate, 2-naphthalanesulfonate, nicotinate, orotate, oxalate, palmitate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, succinate, sulphate, tartrate, thiocyanate, tosylate, trichloroacetate, trifluoroacetate, and undecanoate salts and acid addition salts of L-carnitine. Preferably, the L-carnitine has low hygroscopicity. Preferred L-carnitine salts include, but are not limited to, L-carnitine L-tartrate, L-carnitine acid fumarate, L- carnitine adipate, and L-carnitine magnesium citrate.
For post-menopausal women, a fat soluble vitamin absorption increasing effective amount is an amount of L-carnitine which increases the intestinal absorption of the fat soluble vitamin in a post-menopausal woman. In a post-menopausal woman, typically from about 10 mg to about 2 g of L-carnitine or pharmaceutically acceptable salt thereof per day and preferably from about 250 to about 750 mg of L-carnitine or pharmaceutically acceptable salt thereof per day is administered. More preferably, from about 400 to about 600 mg of L-carnitine or pharmaceutically acceptable salt thereof per day is administered to a post- menopausal woman. Generally, from about 50 to about 800 mg and preferably from about 100 to about 400 mg of L-carnitine or pharmaceutically acceptable salt thereof per 1,000 kcal of diet is administered to a post-menopausal woman. The term “diet” as used herein in reference to post-menopausal women is defined as the amount of food (in calories) consumed " by a woman per day.
For a lower animal, e.g. mammals, a fat soluble vitamin absorption increasing ) effective amount is an amount of L-carnitine which increases the intestinal absorption of the fat soluble vitamin in an animal. The amount of L-carnitine administered to the lower animal may vary depending on age or disease condition of the animal. Generally, from about 1 to about 100 mg/kg of body weight, preferably from about 5 to about 75 mg/kg of body weight,
- and more preferably fro. about 5 to about 25 mg/kg of body weight of L-carnitine or : pharmaceutically acceptable salt thereof is administered to a lower animal. Generally, from about 25 to about 5000 mg/kg of diet, preferably from about 50 to about 1000 mg/kg of diet, : and more preferably from about 75 to about 500 mg/kg of diet of L-carnitine or pharmaceutically acceptable salt thereof is administered to a lower animal. The term “diet” as used herein for non-human (or lower) animals is defined as the amount of food (by weight) consumed by the animal per day.
Suitable fat soluble vitamins include, but are not limited to, vitamin A; vitamin
D; vitamin E (and in particular a-tocopherol); their precursors, such as vitamin E acetate; . 10 esters having 1 to about 20 carbon atoms, such as vitamin A palmitate and vitamin E acetate; and any combination of any of the foregoing. According to one embodiment of the invention, the fat soluble vitamin is vitamin E. The term “vitamin E” as used herein includes a-, f-, 3-, and y-tocopherols and their corresponding acylesters. The amount of a particular fat soluble vitamin administered daily to a post-menopausal woman may be that as recommend by the
U.S.RDA published by the National Academy of Science. Typically, from about 8 to about 800 mg of vitamin E is administered daily to a post-menopausal woman. Preferably, from about 8 to about 400 mg of vitamin E is administered daily to a post-menopausal woman.
The amount of a particular fat soluble vitamin administered daily to a lower animal may be that as recommend by the various animal organizations. The amount of fat soluble vitamin administered may vary depending on age or disease condition of the animal and depending on the vitamin supplemented. Generally, from about 30 to about 5,000 international units (IU)/kg of diet and preferably from about 100 to about 1,000 [U/kg of diet of vitamin FE is administered to a lower animal. Generally, from about 5,000 to about 1,000,000 IU/kg of diet and preferably from about 10,000 to about 500,000 IU/kg of diet of 95 vitamin A is administered to a lower animal. Generally, from about 250 to about 10,000
IU/kg of diet and preferably from about 500 to about 3,000 IU/kg of diet of vitamin D is "administered to a lower animal.
The lower animal may be a household pet, such as a cat or dog. Preferably, the kX animal is a spayed or neutered animal and in particular a spayed or neutered cat or dog.
Preferably, the L-carnitine and fat soluble vitamin are administered concurrently and more preferably in the same dosage unit form to the post-menopausal woman or lower animal. The L-carnitine and fat soluble vitamin are preferably administered during or after a meal.
. - 8 -
Estrogen may also be administered to the post-menopausal womear-with the L- : carnitine and fat soluble vitamin to further enhance the antioxidant system of the post- menopausal woman. The amount of estrogen may be determined by methods known in the : art of estrogen replacement therapy. Generally, from about 300 to about 600 pug of estrogen
S are administered with the L-carnitine and fat soluble vitamin to a post-menopausal woman.
Since L-carnitine in combination with fat soluble vitamins enhances the antioxidant defense mechanism, L-carnitine and a fat soluble vitamin may be administered to reduce the risk or prevent certain degenerative diseases, such as coronary heart disease, age- related macular degeneration, osteoporosis, cancer, and Alzheimer's, in post-menopausal women. The method of the present invention may be used as a prolonged treatment, i.e. for months, vears, or the rest of the person’s life, to reduce the risk of acquiring the aforementioned diseases.
In like manner, L-carnitine may be administered to lower animals to reduce the risk or prevent certain degenerative diseases, such as heart diseases, including coronary heart disease; kidney diseases; urinary diseases; and cancer. The method of the present invention may be used as a prolonged treatment, i.e. for months, years, or the rest of the animal’s life, to reduce the risk of acquiring the aforementioned diseases.
The L-carnitine, fat soluble vitamin, and, optionally, estrogen may be formulated into an oral dosage unit form for post-menopausal women, including, but not limited to, capsules, tablets, and particles, such as powders and sachets, by methods known in the art. The dosage unit form for post-menopausal women may be in liquid or solid form, but is preferably in solid form. The dosage unit form may further comprise additives including, but not limited to, a pH adjuster, a preservative, a flavorant, a taste-masking agent, © a fragrance, a humectant, a tonicifier, a colorant, a surfactant, a plasticizer, a lubricant, a dosing vehicle, a solubilizer, an excipient, a diluent, a disintegrant, or any combination of any of the foregoing. :
Also, for lower animals, the L-carnitine and fat soluble vitamin may be formulated into an oral dosage unit form, including, but not limited to, food, such as animal ) treats; capsules; tablets; and particles, such as powders and sachets, by methods known in the art. The L-carnitine and fat soluble vitamin may be administered to animals through food, water, animal treat, tablet, or capsule. The dosage unit form for lower animals may be in liquid or solid form. The dosage unit form may further comprise any of the aforementioned additives.
Description of the Preferred Embodiments ‘ The following examples illustrate the invention without limitation. All parts and percentages are given by weight unless otherwise indicated.
Example 1
Dietary carnitine increases the liver levels and biliary secretion of a-tocopherol in ovariectomized rats
This study was conducted to determine if dietary carnitine affects the liver concentration and biliary secretion of a-tocopherol in ovariectomized rats.
Materials and Methods:
Thirty two 10 weeks old female Sprague-Dawley rats weighing 214 + 6g (Harlan Sprague Dawley, Indianapolis, IN) were placed individually in plastic cages with stainless steel wire-bottoms in a windowless room at a controlled temperature of about 23°
C and subjected to a light-dark cycle with the light period from 3:30 pm to 3:30 am and the dark period from 3:30 am to 3:30 pm. The rats were acclimatized for 1 week with free access to the deionized water and ad libitum fed a zinc-adequate AIN-93G diet (Reeves et al., J Nutr 1993:123:1939-1951) formulated by Dyets, Inc. (Bethlehem, PA, USA) with 7% soybean oil as a fat source. Zinc carbonate was added to provide the desired levels of zinc. At the end of the first week, at the average body weight of 230£12 g, the rats were ovariectomized under halothane anesthesia after 16 hours of fasting. Initial blood samples (week 0) were taken from 5 randomly selected rats.
After 1 week of postoperative recovery, rats were divided into the following two experimental groups by matching body weight: One group of rats was fed a zinc-adequate
AIN-93G diet containing o-tocopherol-stripped soybean oil; 150 ppm Sipernat™ 50, which is hydrated silica available from Degussa Corporation, Ridgefield, NJ; and supplemented with 150 mg/kg L-carnitine. A control group was fed the same diet, except that the 150 mg/kg of ' L-carnitine was substituted with 150 ppm of a-D-glucose. The normal food intake for both groups was around 15 g/day/rat. Blood samples were taken at the beginning of 1, 3, 5, 8 weeks from 5 randomly selected rats in each group.
At the end of the 8th week, bile duct cannulation was performed on the rats in both groups having an average body weight of about 340+15g. Cannulation of the common bile duct was performed, following 16 hours food deprivation, as described previously (Noh et al., J Nutr Biochem 1999;10:110-117). Briefly, after performing a midline abdominal : incision, the common bile duct was cannulated with PE-10 tubing (Clay Adams. Sparks. MD) under halothane anesthesia (2.0% halothane in 2.0 1 oxygen/min). A silicone feeding catheter y (Silastic medical grade tubing, Dow Corning, Midland, MI) was inserted into the gastric fundus region. The infusion catheter was exteriorized alongside the bile cannula through the right flank. Cannulated rats were placed in individual restraining cages and allowed to recover for at least 20 hours in a warm recovery chamber kept at about 30°C. Immediately after surgery, glucose-phosphate buffered saline (PBS) (in mmol/l: 277 glucose, 6.75 Na,HPO, 16.5 NaH,PO ,, 115 NaCl, and 5 KCI; pH 6.7) was continuously infused through the duodenal cannula at 3.0 ml/h via a syringe pump (Harvard Apparatus, Model 935, South Natick, MA).
After postoperative recovery, rats were infused with a lipid emulsion containing 565 xmol triolein (95%, Sigma Chemical, St. Louis, MO), and 396 umol sodium taurocholic acid in 24 m1 of PBS. Bile was collected hourly for 8 hours in pre-weighed conical centrifuge tubes containing 30 ug of n-propyl gallate in ice filled beakers. After bile collection, the rats were killed by cervical dislocation, and the livers were dissected. The samples were stored at about -70 °C until analysis.
Lipids were extracted by Folch's method (Folch et al., J Biol Chem 1957;226:497-509). The content of a-tocopherol was determined as described by Zaspel et al. (Anal. Biochem. 1983;130:146-150). Briefly, 150 uL of bile and a certain amount of a tocopherol acetate (as internal standard) were pipetted into a glass test. After acetone extraction, sodium sulfate drying, and centrifugation at 1000xg, the upper phase was filtered through a PTFE syringe filter (0.45 xm, Alltech Associates, Inc., Deerfield, IL), dried under
N, gas and resolubilized in a defined volume of chloroform-methanol (1:3, v/v). The extracts were separated on a Beckman HPLC system having System Gold software (Beckman
Instruments, Inc., Fullerton, CA) equipped with a C-18 reverse-phase column (Alltima C18, 5 um, 4.6 x 150 mm, Alltech Associates, Inc., Deerfield, IL). Degassed methanol was used as the mobile phase at 2 ml/min. Typical retention times were 4.1 min for a-tocopherol and 5.3 min for a-tocopherol acetate. Detection was monitored at 292 nm (Module 166 UV- ' detector, Beckman Instruments). Alpha-tocopherol standard curve range was from 47.6 to 190.5 ng.
Statistical analyses were conducted using Excel 97 (Microsoft Inc, 1997) and
PC SAS (SAS Institute, 1996). Student's t-test and a one-way ANOVA were used to compare group means. Differences were considered to be significant at P <0.05.
Results: : No difference was noted in bile flow (7.9 = 1.4 ml/8 hours in the carnitine group vs. 8.9 = 1.8 ml/8 hours in the control group). However, the biliary secretion of a - tocopherol for 8 hours was significantly (P < 0.05) higher in the carnitine group (53.1 9.3 nmol) than in the control group (41.3 = 7.3 nmol). Figures 1 and 2 graphically illustrate the output rate and cumulative output of a-tocopherol, respectively. The liver concentration of a— tocopherol was also significantly elevated in the camitine group (129.6 = 19.5 nmol/g) compared with the control group (100.7 + 20.2 nmol/g). Likewise, the a—tocopherol concentration per 100 mg total lipid was significantly higher in the rats fed a carnitine supplemented diet. The ratio of liver a—tocopherol/phospholipid was significantly (P =0.001) higher in the camitine group (4.8 % 0.6 nmol/umol) than in the control group (3.3 + 0.4 nmol/umol). These findings provide evidence that dietary carnitine improves the liver status of a—tocopherol in ovariectomized rats. 13 Example 2
Dietary carnitine enhances the lymphatic absorption of a-tocopherol in ovariectomized rats
This study was conducted to determine if dietary carnitine improves the intestinal absorption of a—tocopherol in ovariectomized rats.
Materials and Methods:
Thirty two 10 weeks old female Sprague-Dawley rats weighing 208 + 8 g (Harlan Sprague Dawley, Indianapolis, IN) were housed and fed as described in Example 1. 75 At the end of second week, at the average body weight of 240 + 9 g, the rats were ovariectomized under halothane anesthesia after 16 hours fasting. Initial (0 week) blood samples were taken from 6 randomly selected rats.
Immediately after surgery, rats were divided into the following two experimental groups as described in Example 1, i.e., one group was fed a diet supplemented with carnitine, and one control group. The normal food intake for both groups was about 15- 16 g/day/rat.
At the end of the 5" week, Lymph duct cannulation was performed on each group having an average body weight of 340 + 15 g. Cannulation of the mesenteric lymph duct was performed, following 16 hours food deprivation, as described previously (Nohetal.,
supra). Briefly, afte: a midline abdominal incision was performed, the mesenteric lymph duct . was cannulated with polvethylene tubing (SV 31 tubing. Dural Plastics, Auburn. Australia) by securing with a drop of cyanoacrylate glue (Krazy Glue, Columbus, OH) under halothane id anesthesia (2.0% halothane in 2.0 oxygen/min). A silicone feeding catheter (Silastic medical grade tubing, Dow Coming, Midland, MI) was inserted into the gastric fundus region. The infusion catheter was exteriorized alongside the lymph cannula through the right flank.
Cannulated rats were placed in individual restraining cages and allowed to recover for at least 20 hours in a warm recovery chamber kept at about 30°C. Immediately following surgery, glucose-phosphate buffered saline (PBS) (in mmol/l: 277 glucose, 6.75 Na,HPO,, 16.5
NaH,PO,, 115 NaCl, and 5 KCI; pH 6.7) was continuously infused through the duodenal cannula at 3.0 ml/h via a syringe pump (Harvard Apparatus, Model 935, South Natick, MA).
After postoperative recovery, rats were infused with a lipid emulsion containing 1 Ci of [carboxyl-"*C]-triolein (specific activity 112.0 mCi/mmol, DuPont NEN,
Boston, MA), 565 umol triolein (95%, Sigma Chemical, St. Louis, MO), 3.56 umol o— tocopherol (all-rac-a-tocopherol, 97%, Aldrich Chemical. Milwaukee, WI), and 396 umol sodium taurocholic acid in 24 ml of PBS. Lymph was collected hourly for 8 hours in pre-weighed conical centrifuge tubes containing 30 ug of n-propyl gallate and 4 mg of
Na,EDTA in ice-filled beakers. After lymph collection, the rats were killed by cervical dislocation, and the livers were collected. The samples were stored at about -70°C until analysis.
From the lipid extracted (Folch et al., supra), tissue total phospholipid was measured colorimetrically by the method of Reheja et al. (J Lipid Res 1973;14:695-697).
Tissue total cholesterol was determined as described by Rudel et al. (J Lipid Res 1973;21:364-366). Alpha—tocopherol was determined as described by Zaspel etal (supra) and in Example 1 above. Statistical analyses were conducted as described in Example 1.
Results:
No difference was noted in lymph flow (22.6 + 4.2 ml/8 hours in the carnitine ) group vs 24.5 + 2.5 ml/8 hours in the control group). The lymphatic absorption of o— tocopherol for 8 hours was significantly (P < 0.05) higher in the carnitine (899 + 200 nmol/8 h) than in the control group (587 + 92 nmol/8 hours). Figures 3 and 4 graphically illustrate hourly absorption rate and cumulative absorption of a-tocopherol, respectively. The absorption of "“C-triolein was slightly increased (P <0.05) in the camitine group (53.5 + 4.0% dose) compared with control rats (47.6 + 5.0% dose). Significant differences were noted in
13 B "the ratios of lymph a—tocopherol/phospholipid (46.9 + 8.8 nmol/umol in the carnitine group . vs 36.3 + 6.2 nmol/wmol in the control group), and of lymph a—tocopherol/cholesterol (82.7 + 17.1 nmol/umol in the carnitine group vs 60.8 + 6.0 nmol/umol in the control group). These v results present the first evidence that dietary carnitine increases the lymphatic absorption of a-tocopherol.
All patents, applications, articles, publications, and test methods mentioned above are hereby incorporated by reference.
Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. Such obvious variations are within the full intended scope of the appended claims.
Claims (1)
- IN THE CLAIMS:1 1. A method for increasing the intestinal absorption of a fat soluble v 2 vitamin in a post-menopausal woman, the method comprising orally administering to a post- 3 menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption 4 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof.1 2. The method of claim 1, wherein the fat soluble vitamin is selected from 2 the group consisting of vitamin A, vitamin D, vitamin E, and any combination of any of the 3 foregoing.1 3. The method of claim 2, wherein the fat soluble vitamin is vitamin E.1 4. A method for increasing the intestinal absorption of a fat soluble 2 vitamin in a post-menopausal woman, the method comprising orally administering to a post- 3 menopausal woman in need thereof, from about 10 mg to about 2 g of L-carnitine or a 4 pharmaceutically acceptable salt thereof per day and from about 8 to about 800 mg of vitaminE.1 5. The method of claim 4, wherein the L-camitine is L-carnitine L-tartrate, 9 L-carnitine acid fumarate, L-carnitine adipate, or L-carnitine magnesium citrate.1 6. The method of claim 4, wherein from about 250 to about 750 mg of L- 2 carnitine is administered per day.1 7. The method of claim 4, wherein from about 8 to about 400 mg of 2 vitamin E is administered per day.1 8. The method of claim 4, further comprising orally administering 2 estrogen in combination with L-carnitine ora pharmaceutically acceptable salt thereof and the 3 vitamin E.1 9. A method for increasing the biliary secretion of a fat soluble vitamin 2 in a post-menopausal woman, the method comprising orally administering to a post-3 menopausal woman in riced thereof, a fat soluble vitamin and a fat soluble vitamin absorption 4 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof. 1 10. A method for increasing the liver concentration of a fat soluble vitamin 2 in a post-menopausal woman, the method comprising orally administering to a post- 3 menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption 4 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof. 1 11. A method of reducing the risk of one or more diseases in a post- 2 menopausal woman selected from coronary heart disease, age-related macular degeneration, 3 osteoporosis, cancer, and Alzheimer's comprising orally administering to a post-menopausal 4 woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof. 1 12. A method for increasing the intestinal absorption of a fat soluble 9 vitamin in an animal, the method comprising orally administering to the animal in need 3 thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount 4 of L-carnitine or a pharmaceutically acceptable salt thereof. 1 13. The method of claim 12, wherein from about 1 to about 100 mg of L- 2 carnitine or a pharmaceutically acceptable salt thereof per kilogram of body weight per day 3 is administered. 1 14. The method of claim 12, wherein from about 25 to about 5000 mg of 2 L-carnitine or a pharmaceutically acceptable salt thereof per kilogram of diet per day is 3 administered. 1 15. The method of claim 12, wherein from about 30 to about 5,000 IU.of N 2 vitamin E per kilogram of diet per day is administered. 1 16. The method of claim 12, wherein from about 5,000 to about 1,000,000 2 IU.of vitamin A per kilogram of diet per day is administered.PCT/US01/07303 1 17. The method of claim 12, wherein from about 250 to about 10,000 IU.of 2 vitamin D per kilogram of diet per day is administered. 1 18. The method of claim 12, wherein the fat soluble vitamin and L- 2 carnitine or pharmaceutically acceptable salt thereof are administered in the form of adosage 3 unit form. 1 19. The method of claim 18, wherein the dosage unit form is a capsule, 2 tablet, powder, or sachet. 1 20. The method of claim 12, wherein the animal is a household pet. 1 21. The method of claim 20, wherein the animal is a cat or a dog. 1 22. The method of claim 20, wherein the animal is spayed or neutered.1 . 23. A method of reducing the risk of one or more diseases in an animal 2 selected from heart diseases, kidney diseases, urinary diseases, and cancer, comprising orally : 3 administering to an animal in need thereof, a fat soluble vitamin and a fat soluble vitamin : 4 absorption increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof. 1 24. Use of a fat soluble vitamin and an effective amount of L-carnitine 2 or a pharmaceutically acceptable salt thereof, capable of oral administration, in the 3 manufacture of a preparation for increasing the intestinal absorption of a fat soluble 4 vitamin in a post-menopausal woman. 1 25. Use of claim 24, wherein the fat soluble vitamin is selected from the 2 group consisting of vitamin A, vitamin D, vitamin E, and any combination of any of the 3 foregoing. 1 26. Use of claim 25, wherein the fat soluble vitamin is vitamin E. AMENDED SHEETPCT/US01/073031 27. Use of from about 10 mg to about 2 g of L-carnitine or a 2 pharmaceutically acceptable salt thereof, and from about 8 to about 800 mg of vitamin E, 3 capable of oral administration, in the manufacture of a preparation for increasing the 4 intestinal absorption of a fat soluble vitamin in a post-menopausal woman. 1 28. Use of claim 27, wherein the L-carnitine is L-carnitine L-tartrate, 2 L-carnitine acid fumarate, L-carnitine adipate, or L-carnitine magnesium citrate. 1 29. Use of claim 27, wherein from about 250 to about 750 mg of L- 2 carnitine is administered per day. 1 30. Use of claim 27, wherein from about 8 to about 400 mg of vitamin 2 Eis administered per day. 1 31. Use of claim 27, further comprising orally administering estrogen 2 in combination with L-carnitine or a pharmaceutically acceptable salt thereof and the 3 vitamin E. 1 32. Use of a fat soluble vitamin and a fat soluble vitamin absorption 2 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, 3 capable of oral administration, in the manufacture of a preparation for increasing the 4 biliary secretion of a fat soluble vitamin in a post-menopausal woman. 1 33. Use of a fat soluble vitamin and a fat soluble vitamin absorption 2 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, 3 capable of oral administration, in the manufacture of a preparation for increasing the liver 4 concentration of a fat soluble vitamin in a post-menopausal woman. 1 34, Use of a fat soluble vitamin and a fat soluble vitamin absorption 2 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, 3 capable of oral administration, in the manufacture of a preparation for reducing the risk AMENDED SHEET. PCT/US01/073034 of one or more diseases in a post-menopausal woman selected from coronary heart disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer’s. 1 35. Use of a fat soluble vitamin and a fat soluble vitamin absorption 2 increasing effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, 3 capable of oral administration, in the manufacture of a preparation for increasing the 4 intestinal absorption of a fat soluble vitamin in an animal. 1 36. Use of claim 35, wherein from about 1 to about 100 mg of L- 2 carnitine or a pharmaceutically acceptable salt thereof per kilogram of body weight per day 3 is administered. 1 37. Use of claim 35, wherein from about 25 to about 5000 mg of L- 2 carnitine or a pharmaceutically acceptable salt thereof per kilogram of diet per day is 3 administered. 1 38. Use of claim 35, wherein from about 30 to about 5,000 IU of 2 vitamin E per kilogram of diet per day is administered. 1 39. Use of claim 35, wherein from about 5,000 to about 1,000,000 IU 2 of vitamin A per kilogram of diet per day is administered. 1 40. Use of claim 35, wherein from about 250 to about 10,000 IU of 2 vitamin D per kilogram of diet per day is administered. 1 41. Use of claim 35, wherein the fat soluble vitamin and L-carnitine or 2 pharmaceutically acceptable salt thereof are administered in the form of a dosage unit 3 form. 1 42. Use of claim 41, wherein the dosage unit form is a capsule, tablet, 2 powder, or sachet.AMENDED SHEETPCT/US01/073031 43. Use of claim 35, wherein the animal is a household pet. 1 44. Use of claim 43, wherein the animal is a cat or a dog. 1 45. Use of claim 43, wherein the animal is spayed or neutered. 1 46. Use of a fat soluble vitamin and an effective amount of L-carnitine or 2 a pharmaceutically acceptable salt thereof, capable of oral administration, in the 3 manufacture of a preparation for reducing the risk of one or more diseases in an animal 4 selected from heart diseases, kidney diseases, urinary diseases, and cancer. 1 47. A substance or composition for use in a method for increasing the 2 intestinal absorption of a fat soluble vitamin in a post-menopausal woman, said substance 3 or composition comprising a fat soluble vitamin and an effective amount of L-carnitine or 4 a pharmaceutically acceptable salt thereof, and said method comprising orally administering said substance or composition to a postmenopausal woman in need thereof. 1 48. A substance or composition for use in a method of treatment of 2 claim 47, wherein the fat soluble vitamin is selected from the group consisting of vitamin 3 A, vitamin D, vitamin E, and any combination of any of the foregoing. 1 49. A substance or composition for use in a method of treatment of 2 claim 48, wherein the fat soluble vitamin is vitamin E. 1 50. A substance or composition for use in a method for increasing the 2 intestinal absorption of a fat soluble vitamin in a post-menopausal woman, said substance 3 or composition comprising from about 10 mg to about 2 g of L-carnitine or a 4 pharmaceutically acceptable salt thereof and from about 8 to about 800 mg of vitamin E, 5 and said method comprising orally administering said substance or composition to a post- 6 menopausal woman in need thereof.AMENDED SHEETPCT/US01/073031 51. A substance or composition for use in a method of treatment of 2 claim 50, wherein the L-carnitine is L-carnitine L-tartrate, L-carnitine acid fumarate, L- 3 camnitine adipate, or L-carnitine magnesium citrate. 1 52. A substance or composition for use in a method of treatment of 2 claim 50, wherein from about 250 to about 750 mg of L-carnitine is administered per day. 1 53. A substance or composition for use in a method of treatment of 2 claim 50, wherein from about 8 to about 400 mg of vitamin E is administered per day. 1 54. A substance or composition for use in a method of treatment of 2 claim 50, further comprising orally administering estrogen in combination with L-carnitine 3 or a pharmaceutically acceptable salt thereof and the vitamin E. 1 55. A substance or composition for use in a method for increasing the 2 biliary secretion of a fat soluble vitamin in a post-menopausal woman, said substance or 3 composition comprising a fat soluble vitamin and an effective amount of L-carnitine or a 4 pharmaceutically acceptable salt thereof, and said method comprising orally administering said substance or composition to a post-menopausal woman in need thereof. 1 56. A substance or composition for use in a method for increasing the 2 liver concentration of a fat soluble vitamin in a post-menopausal woman, said substance 3 or composition comprising a fat soluble vitamin and an effective amount of L-carnitine or 4 a pharmaceutically acceptable salt thereof, and said method comprising orally 5 administering said substance or composition to a post-menopausal woman in need thereof. 1 57. A substance or composition for use in a method for reducing the risk 2 of one or more diseases in a post-menopausal woman selected from coronary heart 3 disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer’s, said 4 substance or composition comprising a fat soluble vitamin and an effective amount of L- 5 carnitine or a pharmaceutically acceptable salt thereof, and said method comprising AMENDED SHEETPCT/US01/073036 administering said substance or composition to a post-menopausal woman in need thereof. 1 58. A substance or composition for use in a method for increasing the 2 intestinal absorption of a fat soluble vitamin in an animal, said substance or composition 3 comprising a fat soluble vitamin and an effective amount of L-carnitine or a 4 pharmaceutically acceptable salt thereof, and said method comprising orally administering said substance or composition to the animal in need thereof. 1 59. A substance or composition for use in a method of treatment of 2 claim 58, wherein from about 1 to about 100 mg of L-carnitine or a pharmaceutically 3 acceptable salt thereof per kilogram of body weight per day is administered. 1 60. A substance or composition for use in a method of treatment of 2 claim 58, wherein from about 25 to about 5000 mg of L-carnitine or a pharmaceutically 3 acceptable salt thereof per kilogram of diet per day is administered. 1 61. A substance or composition for use in a method of treatment of 2 claim 58, wherein from about 30 to about 5,000 IU of vitamin E per kilogram of diet per 3 day is administered. 1 62. A substance or composition for use in a method of treatment of 2 claim 58, wherein from about 5,000 to about 1,000,000 IU of vitamin A per kilogram of 3 diet per day is administered. 1 63. A substance or composition for use in a method of treatment of 2 claim 58, wherein from about 250 to about 10,000 IU of vitamin D per kilogram of diet 3 per day is administered. 1 64. A substance or composition for use in a method of treatment of 2 claim 58, wherein the fat soluble vitamin and L-carnitine or pharmaceutically acceptable 3 salt thereof are administered in the form of a dosage unit form.AMENDED SHEET. PCT/US01/073031 65. A substance or composition for use in a method of treatment of 2 claim 64, wherein the dosage unit form is a capsule, tablet, powder, or sachet. 1 66. A substance or composition for use in a method of treatment of 2 claim 58, wherein the animal is a household pet. 1 67. A substance or composition for use in a method of treatment of 2 claim 66, wherein the animal is a cat or a dog. 1 68. A substance or composition for use in a method of treatment of 2 claim 66, wherein the animal is spayed or neutered. 1 69. A substance or composition for use in a method for reducing the risk 2 of one or more diseases in an animal selected from heart diseases, kidney diseases, urinary 3 diseases, and cancer, said substance or composition comprising a fat soluble vitamin and 4 an effective amount of L-carnitine or a pharmaceutically acceptable salt thereof, and said method comprising orally administering said substance or composition to an animal in 6 need thereof.AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18841900P | 2000-03-10 | 2000-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200207235B true ZA200207235B (en) | 2003-12-09 |
Family
ID=32592600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200207235A ZA200207235B (en) | 2000-03-10 | 2002-09-09 | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200207235B (en) |
-
2002
- 2002-09-09 ZA ZA200207235A patent/ZA200207235B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qureshi et al. | Synergistic effect of tocotrienol-rich fraction (TRF25) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans | |
JP2012162537A (en) | Method for increasing intestinal absorption of fat soluble vitamin in post-menopausal woman and lower animal | |
US7060263B2 (en) | Super absorption Coenzyme Q10 | |
PT724877E (en) | FENOFIBRATE AND VITAMIN E ASSOCIATION, USE IN THERAPEUTICS | |
CA2891164A1 (en) | Transmucosal delivery of tocotrienol | |
JP2002534445A (en) | Method for lowering blood cholesterol and / or blood triglyceride | |
CA2847543C (en) | Annatto extract compositions, including geranyl geraniols and methods of use | |
EP1748774B1 (en) | Compositions comprising flavonoids and tocotrienols and uses thereof | |
AU2001249106A1 (en) | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals | |
WO2002022146A2 (en) | Components of canola for treating hyperlipidemia | |
ZA200207235B (en) | Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals. | |
WO2001068101A1 (en) | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol | |
JP4896531B2 (en) | Pharmaceutical composition for increasing blood CoQ10 level | |
Schwalbe et al. | Utilization of oral and parenteral applicated tocopheryl acetate | |
Ghulam Rasool | Effect Of Commercially Available Vitamin E Preparations On Arterial Compliance And Selected Cardiovascular Parameters [QP772. T6 A288 2006 f rb]. | |
Besnier et al. | Effects of calcium and vitamin D supplementation in the elderly on discontinuous exteral nutrition (DEN) | |
Elmadfa et al. | Bioavailability of vitamins A, D, E and K as influenced by low oral fish oil supply for 4 weeks in adult males | |
Hillmann et al. | Vitamin-study in patients with Crohn's disease | |
EBAN et al. | EFFECTS OF VITAMIN C, E AND GARLIC ON SERUM ENZYMES AND LIPID PROFILE OF TRAMADOL-INDUCED TOXICITY IN VVISTAR |